GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe 11:18:45 2024-05-23 am EDT 5-day change 1st Jan Change
1,773 GBX -0.85% Intraday chart for GSK plc -0.36% +22.53%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Health Care Up as Vaccine Makers Gain - Health Care Roundup DJ
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
News Highlights : Top Company News of the Day - Wednesday at 1 AM ET DJ
GSK Says Depemokimab Reduced Asthma Attacks in 2 Late-Stage Studies MT
GSK's Potential Blockbuster Asthma Drug Shows Promise in Latest Trial -- 2nd Update DJ
News Highlights : Top Company News of the Day - Tuesday at 7 AM ET DJ
GSK Potential Blockbuster Asthma Drug Shows Promise in Latest Trial -- Update DJ
GSK: positive results for depemokimab in severe asthma CF
GSK's depemokimab asthma treatment meets endpoints in latest trials AN
GSK's experimental drug shows promise in reducing severe asthma attacks RE
GSK's Asthma Drug Reduces Severe Attacks in Late-stage Studies MT
GSK Sees Positive Results for Severe Asthma Treatment Depemokimab DJ
GSK's asthma drug shows promise in reducing severe attacks RE
GSK Reports Positive Phase III Asthma Results For Depemokimab RE
AstraZeneca aims for $80 bln in total revenue by 2030 RE
GSK Faces Whistleblower Lawsuit for Allegedly Hiding Antacid Zantac's Cancer Risks MT
GSK faces whistleblower lawsuit over Zantac cancer risk RE
Lab at Heart of Zantac Cancer Claims Files Whistleblower Lawsuit Against GSK MT
GSK executive buys GBP20,026 worth shares AN
UK's FTSE 100 Closes Lower Amid Inflation Focus MT
Marti Technologies Hires Oguz Erkan as CFO MT
GSK Sells Remaining Stake in Haleon for $1.58 Billion MT
FTSE 100 slides; Eurozone inflation steady AN
London stocks dip as global rates outlook weighs RE
GSK: sale of remaining stake in Haleon CF
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
17.88 GBP
Average target price
20.32 GBP
Spread / Average Target
+13.63%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. US FDA Accepts GSK's Meningococcal Disease Vaccine Candidate for Regulatory Review